Development and validation of a prediction model using molecular marker for long-term survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy.
Yufan YangTao ZhangZongmei ZhouJun LiangDongfu ChenQin-Fu FengZefen XiaoZhouguang HuiJima LvLei DengXin WangWenqing WangJianyang WangWenyang LiuYirui ZhaiJie WangNan BiLuhua WangPublished in: Thoracic cancer (2021)
The nomogram incorporating EGFR mutation status could facilitate survival prediction and risk stratification for individual stage III NSCLC, providing information for enhanced immunotherapy decision and future trial design.
Keyphrases
- small cell lung cancer
- locally advanced
- rectal cancer
- epidermal growth factor receptor
- phase iii
- squamous cell carcinoma
- advanced non small cell lung cancer
- study protocol
- current status
- phase ii
- lymph node metastasis
- radiation therapy
- tyrosine kinase
- clinical trial
- brain metastases
- free survival
- liver metastases
- health information
- decision making
- single molecule
- randomized controlled trial
- newly diagnosed